|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8,252.00 JPY | -3.98% |
|
-2.01% | +0.11% |
| 12-30 | Chugai Completes Merger With Renalys Pharma | MT |
| 12-30 | Chugai Pharmaceutical Co., Ltd. completed the acquisition of Renalys Pharma. | CI |
| Capitalization | 13,580B 85.93B 74.08B 68.97B 64.2B 120B 7,797B 129B 793B 313B 3,719B 322B 316B | P/E ratio 2025 * |
31.7x | P/E ratio 2026 * | 28.1x |
|---|---|---|---|---|---|
| Enterprise value | 12,710B 80.43B 69.34B 64.55B 60.09B 112B 7,298B 120B 742B 293B 3,481B 302B 295B | EV / Sales 2025 * |
10.2x | EV / Sales 2026 * | 9.36x |
| Free-Float |
38.09% | Yield 2025 * |
3.08% | Yield 2026 * | 1.56% |
Last Transcript: Chugai Pharmaceutical Co., Ltd.
| 1 day | -3.98% | ||
| 1 week | -2.01% | ||
| Current month | +0.11% | ||
| 1 month | +0.92% | ||
| 3 months | +19.92% | ||
| 6 months | +19.25% | ||
| Current year | +0.11% |
| 1 week | 8,204 |  | 8,765 |
| 1 month | 8,190 | | 8,765 |
| Current year | 8,204 | | 8,765 |
| 1 year | 5,942 | | 8,765 |
| 3 years | 3,203 | | 8,765 |
| 5 years | 3,191 | | 8,765 |
| 10 years | 1,003.33 | | 8,765 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 62 | 01/01/2021 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | - | 28/03/2024 |
Junichi Nezu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Masayuki Oku
BRD | Director/Board Member | 81 | 01/03/2015 |
Motoo Ueno
BRD | Director/Board Member | 68 | 01/03/1993 |
James H. Sabry
BRD | Director/Board Member | 67 | 01/03/2019 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +2.59% | 6.57% | 27 M€ | |
| +6.99% | 1.87% | 68 M€ | |
| +5.04% | 1.59% | 5 M€ | |
| +7.15% | 1.53% | 79,646 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.98% | -2.01% | +24.60% | +156.67% | 85.93B | |
| +0.53% | -2.37% | +43.09% | +190.27% | 930B | |
| -0.41% | +6.98% | +48.72% | +26.86% | 527B | |
| -0.31% | -2.60% | +24.94% | +40.25% | 379B | |
| +0.93% | +2.38% | +31.46% | +18.47% | 371B | |
| +0.19% | -1.15% | +28.47% | +21.14% | 292B | |
| +0.98% | +1.37% | +29.42% | +35.03% | 276B | |
| -1.93% | -1.54% | +11.14% | -1.47% | 270B | |
| +6.49% | +1.95% | -32.44% | -18.44% | 268B | |
| +0.12% | +1.32% | +21.43% | +22.64% | 178B | |
| Average | +0.26% | +0.43% | +23.08% | +49.14% | 357.69B | |
| Weighted average by Cap. | +0.48% | +0.44% | +28.94% | +67.42% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1,248B 7.9B 6.81B 6.34B 5.9B 10.98B 716B 11.82B 72.9B 28.74B 342B 29.61B 29B | 1,334B 8.44B 7.28B 6.77B 6.31B 11.74B 766B 12.63B 77.92B 30.73B 365B 31.65B 31B |
| Net income | 429B 2.71B 2.34B 2.18B 2.03B 3.77B 246B 4.06B 25.04B 9.87B 117B 10.17B 9.96B | 483B 3.06B 2.64B 2.45B 2.28B 4.25B 277B 4.58B 28.23B 11.13B 132B 11.47B 11.23B |
| Net Debt | -870B -5.5B -4.75B -4.42B -4.11B -7.66B -499B -8.24B -50.82B -20.04B -238B -20.64B -20.22B | -1,094B -6.92B -5.97B -5.56B -5.17B -9.63B -628B -10.36B -63.91B -25.2B -300B -25.96B -25.43B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 8,252.00 ¥ | -3.98% | 2,142,100 |
| 15/01/26 | 8,594.00 ¥ | +0.77% | 2,264,500 |
| 14/01/26 | 8,528.00 ¥ | +1.08% | 1,951,300 |
| 13/01/26 | 8,437.00 ¥ | +0.19% | 2,181,100 |
| 09/01/26 | 8,421.00 ¥ | -0.87% | 2,208,400 |
Delayed Quote Japan Exchange, January 16, 2026 at 02:30 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4519 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition